EA202092980A3 - PHARMACEUTICAL COMPOSITION FOR PARENTERAL DROP INJECTION - Google Patents

PHARMACEUTICAL COMPOSITION FOR PARENTERAL DROP INJECTION

Info

Publication number
EA202092980A3
EA202092980A3 EA202092980A EA202092980A EA202092980A3 EA 202092980 A3 EA202092980 A3 EA 202092980A3 EA 202092980 A EA202092980 A EA 202092980A EA 202092980 A EA202092980 A EA 202092980A EA 202092980 A3 EA202092980 A3 EA 202092980A3
Authority
EA
Eurasian Patent Office
Prior art keywords
acid
pharmaceutical composition
parenteral
treatment
phosphate
Prior art date
Application number
EA202092980A
Other languages
Russian (ru)
Other versions
EA202092980A2 (en
Inventor
Виктор Александрович Сисев
Original Assignee
Общество с ограниченной ответственностью "Ай Кью Витаминная студия"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество с ограниченной ответственностью "Ай Кью Витаминная студия" filed Critical Общество с ограниченной ответственностью "Ай Кью Витаминная студия"
Publication of EA202092980A2 publication Critical patent/EA202092980A2/en
Publication of EA202092980A3 publication Critical patent/EA202092980A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение относится к области фармацевтической промышленности, а именно к фармацевтической композиции для парентерального капельного введения, предназначенной для лечения неинфекционных заболеваний печени. Предложенная композиция содержит комплекс активных веществ: 10-30 мг флавинадениндинуклеотида натрия, 100 мг никотинамидадениндинуклеотидфосфата, 60 мг пиридоксальфосфат гидрата, 1 мг метилкобаламина, 600-3000 мг глутатиона, 12,5 мг оротовой кислоты, 12,5 мг аденозина фосфата, 106 мг моноаммоний глицирризината (80 мг в пересчете на глицирризиновую кислоту), 750 мг L-метионина, 200 мг L-цистеин гидрохлорида, 800 мг L-глицина, 100-250 мг декспантенола, 1-3 мг биотина, 15 мг фолиевой кислоты, 25 мг альфа-липоевой (тиоктовой) кислоты, 25 мг убидекаренона, 1000 мг аскорбиновой кислоты и дистиллированную воду (до 500 мл). Изобретение обеспечивает расширение арсенала средств для лечения патологических процессов в печени неинфекционного генеза.The invention relates to the field of the pharmaceutical industry, namely to a pharmaceutical composition for parenteral drip administration, intended for the treatment of non-infectious liver diseases. The proposed composition contains a complex of active substances: 10-30 mg sodium flavin adenine dinucleotide, 100 mg nicotinamide adenine dinucleotide phosphate, 60 mg pyridoxal phosphate hydrate, 1 mg methylcobalamin, 600-3000 mg glutathione, 12.5 mg orotic acid, 12.5 mg adenosine phosphate, 106 mg monoammonium glycyrrhizinate (80 mg in terms of glycyrrhizic acid), 750 mg L-methionine, 200 mg L-cysteine hydrochloride, 800 mg L-glycine, 100-250 mg dexpanthenol, 1-3 mg biotin, 15 mg folic acid, 25 mg alpha -lipoic (thioctic) acid, 25 mg of ubidecarenone, 1000 mg of ascorbic acid and distilled water (up to 500 ml). The invention provides an expansion of the arsenal of means for the treatment of pathological processes in the liver of non-infectious genesis.

EA202092980A 2019-11-28 2020-12-29 PHARMACEUTICAL COMPOSITION FOR PARENTERAL DROP INJECTION EA202092980A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2019138569A RU2720134C1 (en) 2019-11-28 2019-11-28 Pharmaceutical composition for parenteral drop introduction

Publications (2)

Publication Number Publication Date
EA202092980A2 EA202092980A2 (en) 2021-05-31
EA202092980A3 true EA202092980A3 (en) 2021-08-31

Family

ID=70415446

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092980A EA202092980A3 (en) 2019-11-28 2020-12-29 PHARMACEUTICAL COMPOSITION FOR PARENTERAL DROP INJECTION

Country Status (2)

Country Link
EA (1) EA202092980A3 (en)
RU (1) RU2720134C1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004289353B2 (en) * 2003-11-12 2011-02-10 Children's Medical Center Corporation Treatment and prevention of liver disease associated with parenteral nutrition (PN)
RU2470655C1 (en) * 2011-07-13 2012-12-27 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии Сибирского отделения РАМН Agent normalising liver mitochondria
WO2016179097A1 (en) * 2015-05-04 2016-11-10 Stella Maris Methods for treating mitochondrial damage diseases
RU2659161C1 (en) * 2017-11-17 2018-06-28 Общество С Ограниченной Ответственностью "Ива Фарм" Pharmaceutical composition comprising glutathione disulphide and glutathione disulfide s-oxide
RU2698396C1 (en) * 2019-06-24 2019-08-26 Виктор Александрович Сисев Pharmaceutical composition for parenteral drop introduction

Also Published As

Publication number Publication date
EA202092980A2 (en) 2021-05-31
RU2720134C1 (en) 2020-04-24

Similar Documents

Publication Publication Date Title
Bourgonje et al. N-acetylcysteine and hydrogen sulfide in coronavirus disease 2019
MX2016006919A (en) Nucleotides for the treatment of liver cancer.
SI3212174T1 (en) Methods for treating filoviridae virus infections
BR112013028907A2 (en) protein-active agent conjugates and method for preparing same
UA107112C2 (en) Activator of soluble guanylate cyclase
EA202090514A1 (en) ANTI-VIRAL AGAINST HEPATITIS IN
CZ18013U1 (en) Combined preparation for enhancement of sperm quality
Muhammad et al. Oncology therapeutics targeting the metabolism of amino acids
MX2010007523A (en) Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents.
RU2016135952A (en) DOPA-DECARBOXYLASE INHIBITOR COMPOSITIONS
MY143549A (en) Compositions for external application, containing adenosyl cobalamin for improvement of skin diseases
WO2009088838A3 (en) Triarylmethane analogs and their use in treating cancers
PH12020550956A1 (en) Sgc stimulators
AR110800A1 (en) METHODS TO INCREASE 2'-DEOXYURIDINE (dUrd) IN BLOOD PLASMA AND THE INHIBITION OF THYMIDYLATE SYNTHASE
MX2021015543A (en) Pyrimidine derivative inhibiting growth of cancer cell and medicinal use thereof.
ES2094702B1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF CANCER DISEASES AND PROCEDURE FOR THEIR PREPARATION.
PE20011223A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING PEMETREXED AND AN ANTIOXIDANT SUCH AS MONOTHIOGLYCEROL, L-CYSTEINE AND THIOGLICOLIC ACID
Bottiglieri et al. S-adenosylmethionine
ITTO20100635A1 (en) POLIDESOSSIRIBONUCLEOTIDI (PDRN) FOR THE USE IN THE TREATMENT OF CONDITIONS OF ACIDOSIS AND POLIDESOSSIRIBONUCLEOTIDES-BASED COMPOSITIONS FOR THE ABOVE USE
AU2015242363A1 (en) Glycolipids and pharmaceutical compositions thereof for use in therapy
EA202092980A2 (en) PHARMACEUTICAL COMPOSITION FOR PARENTERAL DROP INJECTION
ITMI20080567A1 (en) L-CITRULLIN FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION AND ERECTILE DYSFUNCTION.
EA202092864A1 (en) PHARMACEUTICAL COMPOSITION FOR PARENTERAL DROP INJECTION
FR2914146B1 (en) PROCESS FOR THE NEMATOCIDAL TREATMENT OF PLANTS BASED ON EUGENOL AND LECITHIN (S) AND / OR DERIVATIVES
Paz-Ares et al. Pemetrexed in bladder, head and neck, and cervical cancers